Status: Not yet recruiting
Study of Intrathecal ELP-02 for Charcot-Marie-Tooth Disease Type 4J (CMT4J)
First-in-human Phase 1/2, open-label study to evaluate the safety, tolerability, and efficacy of a single lumbar intrathecal dose of ELP-02 to individuals with CMT4J.
Participants needed: 8
Trial details
Phase: Phase 1, Phase 2Age: 3-20Biological sex: AllType: InterventionalSponsor: Elpida Therapeutics SPCUpdated: Mar 3, 2026
Eligibility criteria
Male and females between the ages of 3 and 20 years at the time of screening. [+7]
Prior or ongoing medical condition, medical history, physical findings, cardiova... [+16]